• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·NURECA.NS
Share

Nureca Limited Stocks

₹ 345.95Last Updated 18.09.2026

Issuer Rating

2/7
Performance

Poor

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 36.08M

₹ 345.95
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditions like nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers. They also provide orthopedic aids such as massagers, pain monitoring devices, posture correctors, and rehabilitation equipment. Further offerings include humidifiers and steamers, personal weighing scales, yoga and exercise accessories, fitness trackers, and dental and personal hygiene essentials. Additionally, Nureca caters to mother and infant care with products like baby feeding accessories, carry cots, baby skincare items, and bottle warmers/sterilizers. They also supply nutritional supplements, weight management aids, and advanced monitoring devices such as ECG machines, activity trackers, and smart scales. These diverse offerings are marketed under their proprietary brands: Dr Trust, Dr Physio, and Trumom. Distribution occurs through a multi-channel approach, utilizing third-party e-commerce platforms, a network of distributors and retailers, as well as their direct-to-consumer website, drtrust.in. Established in 2016, Nureca Limited is headquartered in Chandigarh, India.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.09.2026 14:53

German stocks rose despite the chancellor's party's poor showing in the election. What's going on?

21.09.2026 14:03

Facebook and Instagram experienced an outage in the U.S.

21.09.2026 13:41

Poland Has Emerged From a 19-Year Stagnation: What Is Driving the Growth of Its Economy and Market

21.09.2026 13:15

"Zero Risk," Sanctions, and AI: Highlights from Revolut CEO's Interview with the Financial Times

21.09.2026 12:46

Brent crude is heading for its longest losing streak since June

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026